CN113278538A - Lactic acid bacteria with high folic acid yield, preparation method and application thereof - Google Patents
Lactic acid bacteria with high folic acid yield, preparation method and application thereof Download PDFInfo
- Publication number
- CN113278538A CN113278538A CN202110225495.8A CN202110225495A CN113278538A CN 113278538 A CN113278538 A CN 113278538A CN 202110225495 A CN202110225495 A CN 202110225495A CN 113278538 A CN113278538 A CN 113278538A
- Authority
- CN
- China
- Prior art keywords
- lactic acid
- folic acid
- agar
- acid bacteria
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 103
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 57
- 239000011724 folic acid Substances 0.000 title claims abstract description 57
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 56
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960000304 folic acid Drugs 0.000 title claims abstract description 46
- 239000004310 lactic acid Substances 0.000 title claims abstract description 28
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 28
- 241000894006 Bacteria Species 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 6
- 229920001817 Agar Polymers 0.000 claims description 23
- 239000008272 agar Substances 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- 229940014144 folate Drugs 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 7
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 7
- 102000002322 Egg Proteins Human genes 0.000 claims description 7
- 108010000912 Egg Proteins Proteins 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 235000015278 beef Nutrition 0.000 claims description 7
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 claims description 7
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 7
- 235000014103 egg white Nutrition 0.000 claims description 7
- 210000000969 egg white Anatomy 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229920000136 polysorbate Polymers 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- 239000012138 yeast extract Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 abstract description 6
- 229940039696 lactobacillus Drugs 0.000 abstract description 6
- 239000003833 bile salt Substances 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 4
- 230000009982 effect on human Effects 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 239000006041 probiotic Substances 0.000 abstract description 4
- 230000000529 probiotic effect Effects 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 239000013586 microbial product Substances 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 description 10
- 238000009630 liquid culture Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ABIUHPWEYMSGSR-UHFFFAOYSA-N bromocresol purple Chemical compound BrC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Br)C(O)=C(C)C=2)=C1 ABIUHPWEYMSGSR-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of lactic acid bacteria, and particularly relates to a lactic acid bacteria with high folic acid yield, a preparation method and application thereof; the invention provides a lactic acid bacterium with high folic acid yield, a preparation method and application thereof; the lactobacillus is bifidobacterium longum BL21 with the preservation number of CGMCC No. 10452; the folic acid obtained by the lactobacillus for high folic acid yield through the microbial product has no side effect on human body, so that the screened probiotic strains which can produce folic acid with high folic acid yield and can be well planted in the human body have high social value, and the yield of the obtained folic acid is higher than that of the existing strains; the lactic acid bacteria with high folic acid yield disclosed by the invention also have the acid resistance and bile salt resistance.
Description
Technical Field
The invention relates to the technical field of lactic acid bacteria, in particular to a lactic acid bacteria with high folic acid yield, a preparation method and an application thereof.
Background
Folic acid is one of B vitamins, can improve memory, delay brain cognitive ability degeneration, and has the function of preventing senile dementia; can soften blood vessel, prevent hypertension and arteriosclerosis; preventing fetal neural tube defect, heart defect, and upper lip crack defect. The human body cannot synthesize folic acid independently, natural folic acid is obtained mainly through food, and anemia and other symptoms are caused by insufficient folic acid intake or malabsorption. The commercially available folic acid tablets are mainly chemically synthesized, are low in safety and free of reducibility, and can cause some adverse reactions after long-term administration. The natural vitamin B group, such as folic acid, biotin, thiamine, nicotinic acid, vitamin B6, riboflavin, vitamin B12, etc., has no side effect on human body. Some microorganisms can synthesize high-activity tetrahydrofolic acid to be directly utilized by human bodies, and the method has good application prospect in food industry. Therefore, the screened probiotic strains capable of producing folic acid with high yield have high social value.
Since folic acid is mainly ingested by food, folic acid deficiency occurs when folic acid is not ingested or the utilization rate of folic acid is reduced. The natural folic acid is mainly derived from folic acid of green foods, animal livers, soybeans and wheat, but the extraction of folic acid from these natural raw materials is costly and not conducive to industrial production. Some microorganisms have the capability of synthesizing B vitamins, including folic acid, biotin, thiamine, nicotinic acid, vitamin B6, riboflavin, vitamin B12 and the like, and the folic acid obtained by the microorganisms has no side effect on human bodies, so that the screened probiotic strains which can produce the folic acid with high yield and can be planted in the bodies well have high social value.
Disclosure of Invention
In view of the above, the present invention provides a lactic acid bacterium with high folate yield, a preparation method thereof and applications thereof.
The technical scheme of the invention is realized as follows:
a lactobacillus for high yield of folic acid is Bifidobacterium longum BL21 with a preservation number of CGMCC No. 10452.
In order to prepare the lactic acid bacteria with high folic acid yield, the invention also provides a preparation method, which comprises the following steps:
s1, screening: obtaining a sample to be screened from saliva and excrement of nature and infants, putting the sample to be screened into a bottle containing normal saline, vibrating and uniformly mixing, and marking an obtained product as bacterial liquid, wherein the mass of the normal saline is 15-20 times of that of the sample to be screened;
s2, dilution: pouring the bacterial liquid obtained in the step 1 into a test tube filled with normal saline to carry out gradient dilution step by 10 times, and marking the obtained product as diluted bacterial liquid;
s3, coating: coating 100 mu L of the diluted bacterial liquid obtained in the step 2 on an agar solid plate by using a coating rod, inverting and putting into an incubator for anaerobic culture for 36-60 h;
s4, purification: after the culture is finished, selecting the agar solid plate with the number of the single colonies larger than 50 on the agar solid plate, and carrying out streak purification on the single colonies on the agar solid plate for multiple times until the microscopic examination forms of the colonies on the whole plate are consistent.
Further, the agar solid plate described in step 3 was prepared by the following steps: 20g of glucose, 0g of chen egg white, 0g g of beef extract, 5g of yeast extract, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 801 g of tween, 0.59g of magnesium sulfate, 0.19g of manganese sulfate monohydrate, 1g of L-cysteine, 1000mL of distilled water and 15g of agar are mixed uniformly, the pH value is adjusted to 6.8 by using sodium hydroxide, and the mixture is sterilized at 121 ℃ for 15 min.
Further, the agar liquid medium described in step 3 is prepared by the following steps: 20g of glucose, 0g of chen egg white, 0g g of beef extract, 5g of yeast extract, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 801 g of tween, 0.59g of magnesium sulfate, 0.19g of manganese sulfate monohydrate, 1g of L-cysteine, 1000mL of distilled water and 15g of agar are mixed uniformly, the pH value of the distilled water is adjusted to 6.8, and the mixture is sterilized at 121 ℃ for 15 min.
Further, after the purification in step 4 is completed, picking the single colony obtained in step 4 to an agar liquid culture medium for propagation, preserving the strain in the agar liquid culture medium containing 30% of glycerol, and freezing and preserving the strain in a refrigerator at-80 ℃.
The invention also discloses application of the high-yield lactic acid bacteria in folic acid production, and folic acid is synthesized by adopting the lactic acid bacteria.
Has the advantages that:
1. the folic acid obtained by the lactic acid bacteria with high folic acid yield through microbial products has no side effect on human bodies, so that the screened probiotic strains which can produce folic acid with high folic acid yield and can be well planted in the bodies have high social value, and the folic acid yield is higher than that of the existing strains.
2. The lactic acid bacteria with high folic acid yield disclosed by the invention also have the acid resistance and bile salt resistance.
Drawings
FIG. 1 is a microscopic picture of a strain of lactic acid bacteria of the present invention with high folate productivity after 16h of plating;
FIG. 2 shows the base sequence of a highly folate-producing lactic acid bacterial strain according to the present invention;
FIG. 3 acid resistance experiment of high folate yielding lactic acid bacterial strains;
FIG. 4 shows the bile salt tolerance test of the high folate yielding lactic acid bacterial strain of the present invention;
FIG. 5 shows the growth curve of the high folate producing lactic acid bacterial strain of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The preparation method of the MRS liquid culture medium comprises the following steps: 20g of glucose, 0g of chen egg white, 0g g of beef extract, 5g of yeast extract, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 801 g of tween, 0.59g of magnesium sulfate, 0.19g of manganese sulfate monohydrate, 1g of L-cysteine, 1000mL of distilled water, pH adjusted by sodium hydroxide to be 6.8, and sterilization at 121 ℃ for 15 min.
The preparation method of the MRS solid culture medium comprises the following steps: 20g of glucose, 0g of chen egg white, 0g g of beef extract, 5g of yeast extract, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 801 g of tween, 0.59g of magnesium sulfate, 0.19g of manganese sulfate monohydrate, 1g of L-cysteine, 1000mL of distilled water, 15g of agar and sodium hydroxide for adjusting the pH value to 6.8, and sterilizing at 121 ℃ for 15 min.
The preparation method of the culture medium of the fermentation infusion bottle comprises the following steps: 25g of glucose, 0g of chen egg white, 0g g of beef extract, 15g of yeast extract, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 801 g of tween, 0.59g of magnesium sulfate, 0.19g of manganese sulfate monohydrate, 1g of L-cysteine, 1000mL of distilled water, pH adjusted by sodium hydroxide to be 6.8, and sterilization at 121 ℃ for 15 min.
EXAMPLE 1 isolation, purification and preservation of the Strain
Screening lactobacillus from saliva and feces of nature and infant. Putting 2g of a sample to be separated into a blue-cap bottle filled with 38mL of physiological saline, shaking and uniformly mixing, gradually diluting with a test tube filled with the physiological saline in a gradient of 10 times, sucking 100 mu L of diluted bacterial liquid by using a pipette, coating the diluted bacterial liquid on an MRS solid plate by using a coating rod, and putting the MRS solid plate into an incubator to perform anaerobic culture for 48 hours in an inverted manner. After the culture is finished, selecting the plate with the number of the single colonies larger than 50 on the plate, selecting the single colonies on the agar solid plate by using the inoculating loop, and streaking and purifying for many times until the colony microscopic examination forms on the whole plate are consistent. Picking single colony to MRS liquid culture medium for propagation, preserving strain in MRS liquid culture medium containing 30% glycerol, and freezing and storing in-80 deg.C refrigerator. A strain of Bifidobacterium longum (number BL 21) is screened out by the method. The strain is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation number is CGMCC No. 10452.
Experimental example 1 preliminary screening of Folic acid-producing Strain
Bromcresol purple was added as an indicator to the Medium FACM (Folic Acid Casei Medium, available from Difco), the pH was adjusted to 6.8, the activated strain was inoculated by sucking 1-2 drops of the liquid with a pipette and incubated at 37 ℃ for 2 days. The medium solution turned yellow, indicating a positive indication that the strain was able to synthesize folate.
Experimental example 2 identification of strains
3.1 colony morphology
Referring to fig. 1, after the strain is cultured in MRS solid medium for 16h, the colony on the plate is smooth, convex, complete in edge, milky white and soft in texture. The single colony is selected for microscopic examination to observe the strain morphology, and the microscopic examination is shown in figure 1.
3.216 identification of S rRNA
Referring to fig. 2, genomic DNA of the target strain was extracted using an Ezup column type bacterial genomic DNA extraction kit, amplified using the extracted lactic acid bacteria strain genomic DNA as a template, and then subjected to PCR experiments using primers for PCR, which were bacterial universal primers 27F and 1492R. And after the PCR amplification reaction is finished, taking the product to dilute to a proper gradient and then carrying out agar gel photographing detection. The amplified product was sent to Biotechnology engineering (Shanghai) Co., Ltd for detection. The nucleotide sequence is shown in FIG. 2. The detection result is compared with a BLAST sequence on an NCBI website, and the result shows that the homology with the 16S rDNA sequence of the bifidobacterium longum is over 99 percent. According to the combination of the morphological observation and the sequence comparison of the strains, the screened lactobacillus strains are determined to be bifidobacterium longum which is preserved in the common microorganism center of China Committee for culture Collection of microorganisms with the preservation number of CGMCC No. 10452.
EXAMPLE 3 determination of Folic acid content
1) Preparing bacterial liquid: after the strain on the plate is selected and activated, the strain is inoculated into an MRS liquid culture medium for 24 hours, and after the strain is cultured, the strain is inoculated into a culture medium of a fermentation infusion bottle in an inoculum size of 2 percent, the culture temperature is 32 ℃, and the culture time is 16 hours.
2) Preparation of a sample to be tested: centrifuging the cultured strain fermentation liquid with high speed centrifuge (10000 rpm, 10min), collecting the centrifuged supernatant, filtering the supernatant with 0.22 μm filter membrane, detecting folic acid content in the supernatant by high performance liquid chromatography, and subtracting folic acid content value in MRS culture medium. The results showed that the folic acid content was 4.1. mu.g/mL.
EXAMPLE 4 growth Curve determination
Referring to fig. 5, after inoculating 2% lactobacillus seed solution in MRS liquid medium, the fermentation broth was taken every 2 hours and the OD600 value of the fermentation broth was measured with a spectrophotometer. The growth curve of the strain was plotted according to the measured data: the strain enters a logarithmic growth phase within about 2 hours, the logarithmic growth phase is finished within about 15 hours, and the strain is shifted into a stationary phase.
EXAMPLE 5 acid resistance test of Strain
Referring to fig. 3, the activated BL21 strain and the control group strain were inoculated into MRS liquid media with pH values of 2.0, 4.0, 5.0, 5.5, 6.0, 6.5, and 7.0, respectively, at a constant temperature of 37 ℃, after 2 hours of culture, viable counts in the media were determined by a spread plate counting method, and the test was repeated 2 times with the MRS media with pH value of 7.0 as a blank, to calculate the effective activities, respectively. BL21 acted for 2h under pH3.0 condition, the survival rate reached 72%.
EXAMPLE 6 bile salt test of Strain
Referring to FIG. 4, the activated BL21 strain and the control group strain were inoculated into MRS media containing 3mg/mL and 6mg/mL cholate according to 3% (v/v) inoculum sizes, respectively, and cultured at a constant temperature of 37 ℃, after 2h of culture, viable count in the media was determined by spread plate counting, and the test was repeated 2 times with the MRS media without cholate as a blank, to calculate the effective activities, respectively. BL21 acted for 2h under the condition of 0.3% of bile salt concentration, and the survival rate was 78%.
The address of the preservation unit of the invention is Beijing in China, and the preservation date is 2015, 01 and 27 days.
Finally, it is to be noted that: the above description is only a preferred embodiment of the present invention, and is only used to illustrate the technical solutions of the present invention, and not to limit the protection scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention shall fall within the protection scope of the present invention.
Claims (6)
1. The lactic acid bacteria with high folic acid yield are characterized in that the lactic acid bacteria are bifidobacterium longum BL21 with the preservation number of CGMCC No. 10452.
2. The method for preparing lactic acid bacteria with high folate yield of claim 1, comprising the following steps:
s1, screening: obtaining a sample to be screened from saliva and excrement of nature and infants, putting the sample to be screened into a bottle containing normal saline, vibrating and uniformly mixing, and marking an obtained product as bacterial liquid, wherein the mass of the normal saline is 15-20 times of that of the sample to be screened;
s2, dilution: pouring the bacterial liquid obtained in the step 1 into a test tube filled with normal saline to carry out gradient dilution step by 10 times, and marking the obtained product as diluted bacterial liquid;
s3, coating: coating 100 mu L of the diluted bacterial liquid obtained in the step 2 on an agar solid plate by using a coating rod, inverting and putting into an incubator for anaerobic culture for 36-60 h;
s4, purification: after the culture is finished, selecting the agar solid plate with the number of the single colonies larger than 50 on the agar solid plate, and carrying out streak purification on the single colonies on the agar solid plate for multiple times until the microscopic examination forms of the colonies on the whole plate are consistent.
3. The method for preparing lactic acid bacteria with high folate according to claim 2, wherein the agar solid plate of step 3 is prepared by the following steps: 20g of glucose, 0g of dried egg white, 10g of beef extract, 5g of yeast extract, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 801 g of tween, 0.59g of magnesium sulfate, 0.19g of manganese sulfate monohydrate, 1g of L-cysteine, 1000mL of distilled water and 15g of agar are mixed uniformly, the pH value is adjusted to 6.8 by using sodium hydroxide, and the mixture is sterilized at 121 ℃ for 15 min.
4. The method for preparing lactic acid bacteria with high folate according to claim 2, wherein the agar liquid medium of step 3 is prepared by the following steps: 20g of glucose, 0g of dried egg white, 10g of beef extract, 5g of yeast extract, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 5g of sodium acetate, 801 g of tween, 0.59g of magnesium sulfate, 0.19g of manganese sulfate monohydrate, 1g of L-cysteine, 1000mL of distilled water and 15g of agar are mixed uniformly, the pH value of the distilled water is adjusted to 6.8, and the mixture is sterilized at 121 ℃ for 15 min.
5. The method for preparing lactic acid bacteria with high folate according to claim 2, wherein after the purification in step 4 is completed, the single colony obtained in step 4 is picked up and spread in agar liquid medium, and the strain is preserved in agar liquid medium containing 30% glycerol and stored in a refrigerator at-80 ℃.
6. The use of a lactic acid bacterium for producing folic acid according to claim 1, characterized in that folic acid is synthesized using said lactic acid bacterium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110225495.8A CN113278538A (en) | 2021-03-01 | 2021-03-01 | Lactic acid bacteria with high folic acid yield, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110225495.8A CN113278538A (en) | 2021-03-01 | 2021-03-01 | Lactic acid bacteria with high folic acid yield, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113278538A true CN113278538A (en) | 2021-08-20 |
Family
ID=77276130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110225495.8A Pending CN113278538A (en) | 2021-03-01 | 2021-03-01 | Lactic acid bacteria with high folic acid yield, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113278538A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117987333A (en) * | 2024-04-07 | 2024-05-07 | 微康益生菌(苏州)股份有限公司 | Composite probiotics for relieving sports fatigue and application thereof |
-
2021
- 2021-03-01 CN CN202110225495.8A patent/CN113278538A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117987333A (en) * | 2024-04-07 | 2024-05-07 | 微康益生菌(苏州)股份有限公司 | Composite probiotics for relieving sports fatigue and application thereof |
| CN117987333B (en) * | 2024-04-07 | 2024-06-07 | 微康益生菌(苏州)股份有限公司 | Composite probiotics for relieving sports fatigue and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109536406B (en) | Weak post-acidification streptococcus thermophilus JMCC16, separation and purification method and application | |
| CN105132318A (en) | Lactobacillus plantarum grx16 and application thereof | |
| CN110734880B (en) | Lactobacillus plantarum Bama06 derived from Guangxi Bama and having high vitamin B yield and application thereof | |
| CN110577912B (en) | Lactobacillus gasseri and application thereof in preparing fermented milk | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| CN112442464B (en) | Bifidobacterium breve grx201 resistant to oxidation stress and application thereof | |
| CN112852684B (en) | Lactobacillus plantarum strain Y388 and application thereof | |
| CN116286468A (en) | Lactobacillus mucilaginosus LF-ONLLY with antioxidant function and application thereof in fermented food | |
| CN111944712B (en) | Lactobacillus plantarum with excellent alcohol tolerance and application thereof | |
| CN113403227A (en) | Lactobacillus plantarum and preparation method and application thereof | |
| CN116103201A (en) | Lactobacillus plantarum LP10 and application, product and method thereof in aspect of producing extracellular polysaccharide and/or antioxidation | |
| CN109504636B (en) | Lactobacillus plantarum P12 and application thereof | |
| CN108004177A (en) | A kind of lactobacillus paracasei and its characteristic research of degradable nitrite | |
| CN112080449B (en) | Enterococcus faecium R40 and application thereof in cholesterol reduction, exopolysaccharide production and antioxidation | |
| CN107828703B (en) | Lactobacillus reuteri Fullarton-9-35 and application thereof | |
| CN107937316B (en) | Space lactobacillus reuteri Fullarton-9-71 and application | |
| CN109645490A (en) | Application of the lactobacillus plantarum CQPC02 in the food or drug of preparation prevention diabetes | |
| CN113278538A (en) | Lactic acid bacteria with high folic acid yield, preparation method and application thereof | |
| CN106119166B (en) | One plant of Switzerland lactic acid bacteria and its application | |
| CN107974424A (en) | Space lactobacillus reuteri Fullarton-9-25 and application | |
| CN116622568A (en) | Lactobacillus harbini P1-1 and application thereof | |
| CN107974425B (en) | Space lactobacillus reuteri Fullarton-9-79 and application | |
| CN113881592B (en) | Lactobacillus reuteri and application thereof | |
| CN112708577B (en) | Lactobacillus fermentum DALI02 with high intestinal adhesion and immunoregulation function and application thereof | |
| CN110241052B (en) | Lactobacillus plantarum GSLP-7 capable of highly producing folic acid and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |